Single-dose dacarbazine and dactinomycin in advanced malignant melanoma
Hochster, H.; Levin, M.; Speyer, J.; Dunleavy, S.; Harris, M.; Roses, D.; Golomb, F.; Muggia, F.
Cancer Treatment Reports 69(1): 39-42
1985
ISSN/ISBN: 0361-5960 PMID: 3967259 Document Number: 245518
Twenty-one patients with advanced malignant melanoma were treated with dacarbazine at a dose of 800 mg/m2 as a single infusion and dactinomycin at a dose of 1.2 mg/m2 every 3 weeks. Hematologic toxicity was mild and gastrointestinal toxicity was tolerable. The response rate for evaluable patients was 22%, which included both men and women with visceral disease. Three of the four responses were complete. Durations of response were 4, 6, 9, and 48+ months. We conclude that dacarbazine can be safely and effectively given as a single dose along with dactinomycin. The possibility that this combination may be more effective than single agents in obtaining complete responses in patients with visceral disease must be explored further.